An article in Benzinga highlights Syqe® Medical’s innovative SyqeAir Inhaler, emphasizing its role in addressing the global challenge of cannabis overdose through metered dosing. CEO of SyqeAir, Hagit Kamin, discusses how the Inhaler and Cartridges allow patients to achieve fast relief in the intensity of chronic neuropathic pain and PTSD symptoms without the risk of overdose. The article underscores Syqe®’s commitment to a safer yet equally effective medical cannabis treatment and marks another prestigious acknowledgment for the company. Read the full article>>
J-Wire & AJN: SyqeAir Inhaler available free to Australian veterans
SyqeAir Inhaler received the Australia’s TGA approval and included in DVA’s funding scheme — enabling eligible veterans to access the treatment at no cost.